U.S. markets closed

22nd Century Group, Inc. (XXII)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9700-0.1300 (-4.19%)
At close: 4:00PM EDT
2.9900 +0.02 (0.67%)
After hours: 05:10PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close3.1000
Bid2.9700 x 3000
Ask3.0300 x 3200
Day's Range2.9050 - 3.0700
52 Week Range0.5800 - 6.0700
Avg. Volume2,101,231
Market Cap483.323M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-0.1370
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 22nd Century Group, Inc
    CARA: What does Argus have to say about CARA?CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Investopedia

    Top Pharmaceutical Stocks for Q4 2021

    These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.

  • GlobeNewswire

    22nd Century Group Enters Global Specialty Hops Market

    Geographic Expansion into Europe via the NetherlandsBUFFALO, N.Y., Aug. 30, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant biotechnology and intellectual property company focused on improving health and wellness through plant science, today announced entry into the global specialty hops market, its third and newest plant franchise. The Company released an update letter to shareholders from CEO James A. Mish describing its opportunities and plans in this market.

  • GlobeNewswire

    22nd Century Group Appoints Accomplished Life Sciences and Biotechnology Executive Anthony Johnson to Board of Directors

    Anthony Johnson Anthony Johnson - Board of Directors Visionary in the Fields of Biotechnology and Genomics to Extend Broad Expertise to Company’s Strategy, Technology Development, Commercialization, and Value Creation Efforts BUFFALO, N.Y., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced the appointment of Anthony Johnson